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Abstract
Background: The Danish Veterinary Cancer Registry (DVCR) was established in May 2005 to gather information
about neoplasms in the Danish dog and cat populations. Practitioners from more than 60 clinics throughout
Denmark have submitted data on these species. The objectives of the current study were, with a special focus on
mast cell tumours (MCT) to investigate the occurrence, gender distribution, biological behaviour, locations, types,
the diagnostic method used and treatment of skin neoplasms in dogs based on information reported to the DVCR.
Methods: From May 15th 2005 through February 29th 2008, reports on a total of 1,768 canine cases of neoplasia in
the skin, subcutis or adnexa were submitted.) Of these, 765 cases (43%) were confirmed by cytology or
histopathology.
Results: The majority of dogs had a benign neoplasm (66%) while 21% were cases of malignant neoplasia. The
most commonly encountered malignant neoplasms were MCT and soft tissue sarcomas and for benign neoplasms,
lipomas and histiocytomas were the most common. The location of the neoplasms were primarily in the cutis,
subcutis or in the perianal region. The occurrence, gender distribution, biological behaviour and location of canine
skin neoplasias in Denmark were similar to earlier reports, although some national variations occurred. A correlation
between grade of MCT and the proportion of cases treated surgically was observed.
Conclusions: Population based cancer registries like the DVCR are of importance in the collection of non-selected
primary information about occurrence and distribution of neoplasms. The DVCR provides detailed information on
cases of skin neoplasms in dogs and may serve as a platform for the study of sub-sets of neoplastic diseases (e.g.
MCT) or subgroups of the canine population (e.g. a specific breed).
Introduction
The skin is the most common anatomical location of
neoplasms and holds between 9.5% and 51% of all
tumours in dogs [1-5]. A wide range of tumour types
can be found in the skin, subcutaneous tissue and
adnexa. However in most studies, the majority of the
neoplasms in the skin were diagnosed as benign, e.g.
adenomas and lipomas.
Diagnosis of skin tumours usually includes evaluation
of cells using cytology and in cases where a biopsy is
taken, histopathology. Furthermore a search for
metastases is warranted. This approach is aimed at grad-
ing and staging the neoplastic disease.
Treatment of skin neoplasms, in particular malignant
tumours, can be challenging. The treatment of choice in
most cases includes surgical excision but depend on the
type of cancer, stage, grade, and location. In some cases
radiation or chemotherapy may be used alone or as
adjunctive therapy of malignant neoplasms. This is typi-
cally the case in chemosensitive neoplasms in tumours
that readily metastasise to distant locations or if com-
plete resection can not be achieved e.g. distally on limbs
or in the head.
Mast cell tumours (MCT), the most common skin
cancer, represents a particular diagnostic and surgical
challenge due to the high degree of behavioural variabil-
ity from seemingly benign to highly malignant [6-8].
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Fine needle aspirations of MCT are usually rich in cells
as these exfoliate easily and cytology is usually sufficient
for a diagnosis of MCT. However for grading of the
tumours, histopathology is necessary. Suggested prog-
nostic factors in MCT include location, grade and stage.
Prediction of outcome and treatment planning should
be based on a panel of prognostic factors, rather than
on a single prognostic factor since no such has proven
superior to predict MCT prognosis alone [9,10]. Treat-
ment of MCT may include surgery, radiation, che-
motherapy or a combination hereof. Dobson and Scase
[2] concluded in a recent review that grade I MCT
require only local resection and grade II MCT may be
successfully treated with a 2 cm margin and one fascial
plane deep resection. Grade III MCT carries a poorer
prognosis but treatment outcome may improve if
adjunctive radiation or chemotherapy is administered.
The objectives of the current study were, with a spe-
cial focus on MCT to investigate the occurrence, gender
distribution, biological behaviour, locations, types, the
diagnostic method used and treatment of skin neo-
plasms in dogs reported to the Danish Veterinary Can-
cer Registry (DVCR). Furthermore the possible
correlation between the diagnostic modality and the
treatment elected will be investigated.
Materials and methods
Canine cases entered in the DVCR from May 15th 2005
through February 29th 2008 were included in this study.
They were selected based on location of a tumour in
the skin, subcutaneous tissue or adnexa. The DVCR is a
database of cases of neoplasia in Danish dogs and cats.
It is an incident registry where each neoplasm is
regarded as a separate entity, and data are collected pro-
spectively. In contrast to other veterinary and human
cancer registries DVCR comprises both benign and
malignant neoplasms, and neoplasms diagnosed using
other diagnostic methods than histology, such as cytol-
ogy, diagnostic imaging etc. (Table 1). The base for the
DVCR has been reported recently.
Data were entered into an Excel spreadsheet and sta-
tistical tests performed in SAS (version 9.1, SAS Insti-
tute, Cary, NC, USA). Chi-square test was used to
analyse proportions of cases having had surgery and his-
topathology or cytology performed. P < 0.05 was consid-
ered to be significant.
Results
A total of 1,768 cases of neoplasia in dogs were entered
into the DVCR during the study period. 765 of these
(43%, confidence interval (CI): 41.0-45.6) were located
Table 1 Most common benign and malignant types of neoplasms in different studies.
Registry Australia
[15]
#, N = 1000
Australia
[16]
#, N = 1000
Greece
[10]
#, N = 174
Korea
[17]
#, N = 748
Distribution benign/malignant B: 41.9%
M: 58.1%
B: 48.2%
M: 52.8%
B: 53.4%
M: 46.6%
B: 69%
M: 31%
Top 3 benign
Pct of all skin tumours
(Pct of all benign tumours)
Basal cell tumour
12.0% (20.7%)
Perianal gl. adenomas
8.3% (19.8%)
Histiocytoma 7.8%
(18.6%)
Histiocytoma 14.0% (29.0%)
Lipoma 6.0% (12.4%)
Basal cell epithelioma 5.5%
(11.4%)
Hepato gl. adenoma 9.8%
(18.3%)
Lipoma 5.7% (10.8%)
Histiocytoma 5.7% (10.8%)
Epidermal cysts 12.7%
(18.3%)
Lipoma 11.4% (16.4%)
Histiocytoma 7.5%
(10.8%)
Top 3 malignant
Pct of total skin (pct of all
malignant skin tumours)
MCT 17.6% (30.3%)
STS 8.5% (14.6%)
Melanoma 6.8%
(11.7%)
MCT 16.1% (31.1%)
STS 14.4% (27.8%)
SCC 6.9% (13.3%)
MCT 13.8% (29.6%)
STS 10.3% (22.2%)
Basal cell carcinoma 4.0% (8.6%)
MCT 8.8% (28.7%)
STS 3.3% (10.9%)
Apocrine
adenocarcinoma 3.1%
(10.0%)
Registry Norway
[1]
#, N = 7401
South Africa
[18]
#; N = 903
USA
[3]
#, N = 277
Distribution benign/malignant M: 22% B: 54.4%
M: 45.6%
M: 100%
Top 3 benign
Pct of all skin tumours
(Pct of all benign tumours)
Epidermal adenoma 22.7%
(29.2%)
Lipoma 13.6% (17.4%)
Histiocytoma 13.3% (17.1%)
Basal cell tumour 18.8% (34.6%)
Perineal gland adenoma 13.4%
(24.6%)
Sebaceous gland adenomas and
cysts 6.1% (11.2%)
-
Top 3 malignant
Pct of total skin (pct of all
malignant skin tumours)
MCT 10.0 (45.4%)
STS 4.3% (19.6%)
Malignant epidermal
tumours 3.4% (15.4%)
SCC 16.4% (35.9%)
Melanoma 11.4% (25.0%)
MCT 8.9% (19.4%)
MCT (27%)
Adenocarcinoma (26%)
Melanoma (22%)
MCT: Mast cell tumours, SCC: Squamous cell carcinoma, STS: Soft tissue sarcoma
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in the skin, subcutis or adnexa and had a diagnosis
established by cytology or histopathology. Another 21
cases without a cytologically or histopathologically con-
firmed diagnosis were reported to the DVCRbut were
omitted from the study.
Of the 765 cases, 400 cases (52%, CI: 48.8-55.8) were
males, including 91 neutered), and 363 reports (48%, CI:
43.9-51.0) were on females, including 103 neutered. In 2
cases, information on gender was provided.
The majority of reports concerned benign tumours
(66%, CI: 62.8-69.5, 506), while 21% (n = 160, CI: 18.0-
23.8) were reports on malignant neoplasms. In 99 cases
(13%, CI: 10.6-15.3) biological behaviour was not pro-
vided. The location of the neoplasms were primarily in
the cutis, subcutis or in the perianal region (Table 2).
The most commonly encountered malignant neo-
plasms were MCT and soft tissue sarcomas (STS) and
for benign neoplasms lipomas and histiocytomas (Table
3).
The majority of cases (62%, CI: 58.4-65.3) were treated
surgically (Table 3). Surgery was performed in 61% (CI:
56.2-64.7) of the benign cases and in 70% (CI, 62.9-77.1)
of the malignant cases. The diagnostic method used to
verify the diagnosis as well as the proportion of cases
where surgery was performed is shown in Table 3.
Microscopic evaluation by cytology or histopathology
wwas the most commonly used diagnostic tool (Table
3). Corticosteroids were administered in 27 cases (4%,
CI: 2.2-4.8). Thirteen of these cases were diagnosed as
MCT and 5 cases were histiocytomas. In 6 cases of
MCT and 1 case of malignant melanoma, corticosteroids
were given in combination with surgery.
Euthanasia was the final outcome in forty patients
(5%, CI: 3.7-6.8) of which 30 had malignant neoplasms,
6 had benign neoplasms and 4 had tumours of unknown
biological behaviour.
In cases where the diagnosis was confirmed by histo-
pathology, surgical excision was performed in 97% (CI:
94.7-99.2) of the benign tumours and in 80% (CI: 72.7-
88.1) of the malignant ones, whereas in cases where the
diagnosis was made by cytology, surgical excision was
only performed in 31% (CI: 25.4-36.2) and 52% (CI:
38.9-64.6) of the benign and malignant cases, respec-
tively. The proportion of cases diagnosed by histopathol-
ogy that had surgical treatment was significantly higher
than the proportion of surgical cases diagnosed by cytol-
ogy (P < 0.0001).
Mast cell tumours
MCT were the most common malignant neoplasms of
the skin. A total of 114 MCT were reported, and their
grade was reported in 51 cases. The diagnostic tool was
cytology in 49 cases and histopathology in 65 cases.
Only in two cases another diagnostic tool was chosen.
Of the graded cases, 17 were reported as grade I, 26 as
grade II and 8 as grade III. MCT were located on the
trunk including the inguinal area in 46 cases (40%, CI:
31.4-49.4), in the perineal-genital area in 5 cases (4%,
CI: 0.6-8.1) and on the extremities in 23 cases (20%, CI:
12.8-27.5). Surgery was performed in 83 out of the 114
cases (73%, CI: 64.6-81.0) including 34 cases of MCT on
the trunk (74%, CI: 61.2-86.6), in 18 cases on extremities
(78%, CI: 61.4-95.1) and in 2 cases of perineal-genital
sites (40%, CI: 0-83.0). Of the graded cases, grade I
MCT were excised in 11 cases (64.7%, CI: 42.0-87.4, of
grade I cases), grade II in 25 cases (96.2%, CI: 88.8-100,
of grade II cases) and grade III in 2 cases (25%, CII 0-
55.0, of grade III cases). The majority of the grade III
cases had either corticosteroid therapy (5 cases) or were
euthanised (2 cases). In 14 cases of MCT, corticosteroid
treatment was given supplementary to surgery. Fifteen
cases had regional or distant metastases; of these 10
cases had surgery (Table 4).
Discussion
Histopathology was used in 46% of all cases of skin neo-
plasia. Biopsy and histopathology without following sur-
gery was only performed in 9.9% of cases but almost all
cases having surgery had specimens submitted for histo-
pathology. This illustrates a common linkage between
these two events. The linkage is most likely due to a
usual procedure including submission of biopsies from
suspected malignant tumors and histopathological
examination of excised malignant tumours post-
operatively.
Table 2 Location and behaviour of neoplasms. Data from the Danish Veterinary Cancer Registry.
Malignant
No (Pct of location)
Benign
No (Pct of location)
Unknown
No (Pct of location)
Total
No (Pct of total)
Cutis 108 (23) 294 (64) 58 (13) 460 (60)
Subcutis 16 (10) 128 (81) 15 (9) 159 (21)
Perianal 15 (20) 49 (66) 10 (14) 74 (10)
Glands 5 (19) 8 (31) 13 (50) 26 (3)
Eyelid 1 (5) 17 (90) 1 (5) 19 (3)
Other 15 (56) 10 (37) 2 (7) 27 (2)
Total 160 (20) 506 (66) 99 (14) 765 (100)
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Cytology was widely used for diagnosis of skin
tumours (54%) and should be included in the registry
data as this method is often the only diagnostic proce-
dure performed. This was especially true for benign
neoplasms.
The proportion of neoplasms located in the skin was
similar to data of a Norwegian study [1]. In an Ameri-
can study including both benign and malignant neo-
plasms, the proportion of tumours located in the skin
was much lower (14.8%) [4]. If only malignant neo-
plasms were considered, the proportion of the malignant
skin neoplasms was 21% in the current study, again
equal to figures of the Norwegian registry (21.7%) [1].
Comparative data from other countries were either
lower or higher (9.5% (Italy) vs. 30.3% (USA)) [3,5].
The male to female ratio (M:F) in this study was 1.1 in
regards to all neoplasms as well as malignant neoplasms
alone. This gender distribution was similar to that found
in the Norwegian as well as a Greek study (M:F 0.85
and 0.89, respectively) [1,10], but very different to an
Italian study in which a majority of females was seen
(M:F 2.58) [1,5].
In other veterinary studies the majority of the skin
neoplasms were benign as in the current study
[1,2,4,10].
In the Norwegian study [1], the most common malig-
nant neoplasia types were MCT (45.4% of all malignan-
cies reported), STS (19.7%) and epithelial tumours
(15.4%) (Table 1). These figures correspond to those
found in the current study. The most common benign
neoplasms in the Norwegian study [1]were epithelial
tumours (29.2% of all benign tumours reported), lipo-
mas (17.4%) and histiocytomas (17.1%), figures being
similar to the current study. In the Italian study mela-
noma constituted only 4.1% of the skin malignancies [5],
much lower than in the current study. The discrepancies
among countries may be due to differences in dog
populations, breed composition as well as cultural differ-
ences in animal management as illustrated previously
[1,11].
Mast cell tumours
A recent review [9], Dobson and Scase discussed the
diagnostic and therapeutic options of cutaneous MCT.
Prognostic factors of significance included grading
(cytology and histopathology), staging (regional and dis-
tant metastases), breed, tumour localisation and treat-
ment (surgery, radiation and chemotherapy). Cytological
examination after fine needle aspiration is useful in
establishing the diagnosis but histopathology is needed
for grading [9].
Prognostic factors such as grade, metastases and
tumour location are registered in the DVCR and the
registry may be used for collection of cases for studies;
both of cases that were treated following the recommen-
dation for MCT treatment and cases that were not. The
latter might provide an insight into the prognosis of ani-
mals where owners rejected surgery or other treatment
options.
Table 3 Most commonly encountered neoplasms including the diagnostic method utilised and percentages of cases
operated
Diagnostic method Histology Cytology Other Total
Type of neoplasia Number/Pct surgery Number/Pct surgery Number/Pct surgery Number/Pct surgery
Lipoma 18/89 164/23 6/33 188/29
MCT 65/53 49/91 2/100 116/75
Histiocytoma 46/98 52/44 2/100 100/70
Adenoma, all 42/98 51/33 2/100 96/63
STS 27/89 8/38 - 35/77
Melanoma 19/95 2/50 - 21/90
Total 354/91 411/36 21/67 786/62
Number: Total number of cases; Pct surgery: percentage of cases operated
MCT: Mast cell tumours, STS: Soft tissue sarcoma
Table 4 Distribution of 114 cases of MCT
Graded as Location Surgery Suppl.
corticosteroids
Euthanasia
Grade I 17 11
Grade II 26 25
Grade III 8 2 5 2
Trunk incl. inguinal 46 34
Perineal-genital 5 2
Extremities 23 18
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Grade II MCT were most often as recommended sur-
gically excised. It was however noted that surgery was
less often performed for both grade I and III tumours.
Grade III tumours have a very poor prognosis even with
treatment, which might discourage owners from exten-
sive surgery. This may explain the discrepancy in sur-
gery performed in MCT cases of different grades.
The location of MCT as a prognostic factor has been
discussed in the literature and neoplasms in the muco-
cutaneous junctions and inguinal region have been
reported as more aggressive and connected to a higher
risk of metastasis than MCT in other locations [9].
However, no single prognostic factor has proven super-
ior in the prediction of MCT prognosis [12]. Surgery
was performed equally often on MCT located on the
trunk and on extremities even though the latter location
often impairs the use of wide surgery margins. Despite
signs of metastases, indicating stage III or IV of the dis-
ease, 10 out of 15 cases had surgery performed. Surgery
may be used as a palliative measure in the treatment of
MCT as metastases can cause significant discomfort in
the patient.
The treatment of choice in grade I and grade II MCT
is surgery as recommended by Dobson and Scase [9]
among others. Surgery should be performed with 2 cm
margins [6,8]. In the current study surgery was per-
formed in 73% of the MCT cases in the DVCR suggest-
ing that cases of MCT are treated according to the
recommendations at the participating veterinary clinics.
Treatment recommendation for high grade MCT
includes both surgery and adjunctive therapy in the
form of radiation or chemotherapy. This is consistent
with the fact that half of the grade III cases had corti-
costeroid treatment. Apart from corticosteroid treatment
and 1 case of chemotherapy, adjunctive therapy was not
pursued in the MCT treatments reported to the DVCR.
This is expected as both therapies are relatively new
modalities in canine cancer treatment in Denmark com-
pared to other countries [13,14].
Other prognostic factors for MCT have been investi-
gated e.g. Ki67 index, c-KIT mutations, mitotic index,
and surgical margins. These parameters were not
included in the DVCR records as they are not routinely
considered in primary practice diagnostic work-up. The
DVCR may be used to locate cases for case-control stu-
dies or for follow-up studies of cases treated following
certain protocols.
The DVCR offers an insight into the actual situation
from primary practice clinics and hospitals among Dan-
ish dogs encountering skin neoplasms. Using MCT as
an example, an attempt was made to outline the diag-
nostic modalities used and the treatments chosen when
dogs are diagnosed (with MCT) outside a clinical trial
setting. This knowledge can help uncover the
consequences of non-consensus treatment, which is gen-
erally based on historical or empiric data. The choice of
treatment is based upon the owners’ choice and depends
on many factors such as financial, ethical, social and
animal welfare considerations. The latter, including sur-
vival time estimates, is an important part of the owner
decision making and while clinical trials and controlled
studies can contribute with information of the likely
consequences of specific treatment regiments the DVCR
might over time be able to uncover the consequences of
the alternatives.
Conclusions
The occurrence, gender distribution, histological malig-
nancy and location of skin neoplasias in Denmark were
in agreement with the majority of earlier reports,
although some unexplained national variations seem to
occur. The most commonly occurring malignant cuta-
neous neoplasms were MCT and STS.
Population based cancer registries like the DVCR are
of importance in order to collect non-selected primary
information of occurrence and distribution of neolasms.
The DVCR provides detailed information on cases of
skin neoplasms in dogs and may serve as a platform for
the study of sub-sets of neoplastic diseases (e.g. MCT)
or subgroups of the canine population (e.g. a specific
breed).
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